New York State Teachers Retirement System Lowers Holdings in Roivant Sciences Ltd. $ROIV

New York State Teachers Retirement System decreased its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 5.3% in the 1st quarter, Holdings Channel.com reports. The fund owned 255,908 shares of the company’s stock after selling 14,313 shares during the quarter. New York State Teachers Retirement System’s holdings in Roivant Sciences were worth $7,089,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ROIV. HighVista Strategies LLC increased its position in shares of Roivant Sciences by 61.4% during the 3rd quarter. HighVista Strategies LLC now owns 98,858 shares of the company’s stock worth $1,496,000 after purchasing an additional 37,590 shares during the last quarter. Pictet Asset Management Holding SA lifted its position in Roivant Sciences by 790.3% in the fourth quarter. Pictet Asset Management Holding SA now owns 2,312,436 shares of the company’s stock valued at $50,180,000 after buying an additional 2,052,693 shares during the last quarter. Capricorn Fund Managers Ltd boosted its stake in Roivant Sciences by 124.4% during the fourth quarter. Capricorn Fund Managers Ltd now owns 445,500 shares of the company’s stock worth $9,667,000 after buying an additional 247,000 shares during the period. Vanguard Group Inc. boosted its stake in Roivant Sciences by 8.4% during the fourth quarter. Vanguard Group Inc. now owns 42,059,041 shares of the company’s stock worth $912,681,000 after buying an additional 3,254,113 shares during the period. Finally, Foursixthree Capital LP increased its position in shares of Roivant Sciences by 4.2% during the third quarter. Foursixthree Capital LP now owns 938,175 shares of the company’s stock valued at $14,195,000 after acquiring an additional 38,175 shares during the last quarter. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, CEO Eric Venker sold 200,000 shares of the stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $33.16, for a total value of $6,632,000.00. Following the sale, the chief executive officer owned 1,613,063 shares of the company’s stock, valued at $53,489,169.08. This trade represents a 11.03% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Matthew Gline sold 289,774 shares of Roivant Sciences stock in a transaction dated Thursday, April 16th. The shares were sold at an average price of $29.16, for a total value of $8,449,809.84. Following the completion of the transaction, the chief executive officer owned 16,736,116 shares of the company’s stock, valued at $488,025,142.56. The trade was a 1.70% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 2,359,225 shares of company stock worth $77,401,516 over the last quarter. 10.80% of the stock is currently owned by insiders.

Roivant Sciences Stock Performance

Shares of NASDAQ:ROIV traded up $0.16 during trading on Tuesday, hitting $35.55. The company’s stock had a trading volume of 576,101 shares, compared to its average volume of 6,084,984. The business has a 50 day moving average price of $30.38 and a two-hundred day moving average price of $27.39. The company has a market capitalization of $25.57 billion, a PE ratio of -59.20 and a beta of 1.11. Roivant Sciences Ltd. has a fifty-two week low of $10.70 and a fifty-two week high of $35.90.

Roivant Sciences (NASDAQ:ROIV) last posted its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.57. The business had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.During the same quarter in the prior year, the company earned ($0.29) earnings per share. As a group, equities analysts expect that Roivant Sciences Ltd. will post -1.83 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ROIV shares. HC Wainwright reissued a “buy” rating and issued a $34.00 price target on shares of Roivant Sciences in a research note on Thursday, May 21st. Citigroup lifted their target price on shares of Roivant Sciences from $35.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, May 21st. Piper Sandler reissued an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, May 21st. Leerink Partners set a $42.00 price target on Roivant Sciences in a research note on Thursday, May 21st. Finally, Weiss Ratings cut Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 22nd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $33.59.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.